Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?

• Published in: Current hypertension reports 2024-12, Vol.26 (12), p.463-474
• Main Authors: Siddiqui, Rehma, Obi, Yoshitsugu, Dossabhoy, Neville R., Shafi, Tariq
• Format: Article
• Language: English
• Subjects: Cardiology; Cardiovascular Diseases - drug therapy; Clinical trials; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Family Medicine; General Practice; Hemodialysis; Humans; Internal Medicine; Kidney diseases; Kidney Failure, Chronic - drug therapy; Mechanisms of Hypertension and Target-Organ Damage (JE Hall and ME Hall; Mechanisms of Hypertension and Target-Organ Damage (JE Hall and ME Hall, Section Editors); Medicine; Medicine & Public Health; Metabolic Diseases; Nephrology; Primary Care Medicine; Renal Dialysis; Section Editors; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Topical Collection on Mechanisms of Hypertension and Target-Organ Damage
• ISSN: 1522-6417; 1534-3111; 1534-3111
• DOI: 10.1007/s11906-024-01314-3

Purpose of Review Chronic kidney disease and end-stage kidney disease (ESKD) are well-established risk factors for cardiovascular disease (CVD), the leading cause of mortality in the dialysis population. Conventional therapies, such as statins, blood pressure control, and renin-angiotensin-aldosterone system blockade, have inadequately addressed this cardiovascular risk, highlighting the unmet need for effective treatment strategies. Sodium–glucose transporter 2 (SGLT2) inhibitors have demonstrated significant renal and cardiovascular benefits among patients with type 2 diabetes, heart failure, or CKD at risk of progression. Unfortunately, efficacy data in dialysis patients is lacking as ESKD was an exclusion criterion for all major clinical trials of SGLT2 inhibitors. This review explores the potential of SGLT2 inhibitors in improving cardiovascular outcomes among patients with ESKD, focusing on their direct cardiac effects. Recent Findings Recent clinical and preclinical studies have shown promising data for the application of SGLT2 inhibitors to the dialysis population. SGLT2 inhibitors may provide cardiovascular benefits to dialysis patients, not only indirectly by preserving the remaining kidney function and improving anemia but also directly by lowering intracellular sodium and calcium levels, reducing inflammation, regulating autophagy, and alleviating oxidative stress and endoplasmic reticulum stress within cardiomyocytes and endothelial cells. Summary This review examines the current clinical evidence and experimental data supporting the use of SGLT2 inhibitors, discusses its potential safety concerns, and outlines ongoing clinical trials in the dialysis population. Further research is needed to evaluate the safety and effectiveness of SGLT2 inhibitor use among patients with ESKD.